Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.
about
Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversiesTargeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast CancerPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsPotentiation of growth factor signaling by insulin-like growth factor-binding protein-3 in breast epithelial cells requires sphingosine kinase activityGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsEHD proteins: key conductors of endocytic transport.Gene expression patterns in pancreatic tumors, cells and tissues.Mammalian Eps15 homology domain 1 promotes metastasis in non-small cell lung cancer by inducing epithelial-mesenchymal transition.Quantitative proteomic profiling studies of pancreatic cancer stem cellsLRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen.Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma.Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathwayUpregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development.Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.Dynamic expression of Tbx2 and Tbx3 in developing mouse pancreasIdentification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1Discovery of novel glucose-regulated proteins in isolated human pancreatic islets using LC-MS/MS-based proteomics.BCL9L expression in pancreatic neoplasia with a focus on SPN: a possible explanation for the enigma of the benign neoplasia.Molecular dynamics simulation of the interactions between EHD1 EH domain and multiple peptides.Pro-oncogenic Roles of HLXB9 Protein in Insulinoma Cells through Interaction with Nono Protein and Down-regulation of the c-Met Inhibitor Cblb (Casitas B-lineage Lymphoma b).LRP5/6 in Wnt signaling and tumorigenesis.Pancreatic cancer cell-derived IGFBP-3 contributes to muscle wastingPancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.omb and circumstance.High RAB25 expression is associated with good clinical outcome in patients with locally advanced head and neck squamous cell carcinoma.Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.Metastasis-associated cell surface oncoproteomics.The targeted therapy revolution in neuroendocrine tumors: in search of biomarkers for patient selection and response evaluation.Molecular pathogenesis of pancreatic neuroendocrine tumors.Gene expression profiles in primary pancreatic tumors and metastatic lesions of Ela-c-myc transgenic mice.Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.The Long Non-Coding RNA MEG3 is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells.UV-mediated regulation of the anti-senescence factor Tbx2.Differential expression of genes encoding proteins of the HGF/MET system in insulinomasPoly(A) RT-PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer.Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression.Diverse functional networks of Tbx3 in development and diseaseClinicopathological significance and impact on outcomes of the gene expression levels of IGF-1, IGF-2 and IGF-1R, IGFBP-3 in patients with colorectal cancer: Overexpression of the IGFBP-3 gene is an effective predictor of outcomes in patients with cDownregulation of miR-186 is associated with metastatic recurrence of gastrointestinal stromal tumors.
P2860
Q24647838-E07878F7-DA68-4820-826A-F0358996AB48Q26801886-68DC713B-BD40-41A2-A34A-0F2A9428303DQ26862544-E7C1C50E-2567-4112-867D-DCD49A54B6A9Q28253045-500271AD-09DB-45D2-A0A8-4E9537477231Q28290833-B4C8DE59-DD53-4540-B64D-4EBA9B288CFDQ30396094-0BF160A9-0897-4062-9EA5-DDCAF9422CE7Q30830632-9F29ACAE-6185-4D0F-BE93-912AA812DBA7Q33618358-173CE64B-7A4B-48D7-935A-CFAC3FE1265DQ34004256-C3DD3796-465A-4D34-A583-614E5D0F6683Q34130203-A3C83203-DB92-4B52-BDE6-2A6CEA73F6EFQ34452650-21C45603-5FCC-49A1-9A87-96666B56E991Q34887795-EF56D298-C786-4FB4-8F43-8F1008CBE0CAQ34972500-18CFED4C-9B1E-453D-904A-BFF731929B0FQ35001398-2140162E-577F-4E2A-8E74-8CB41263004CQ35054978-9B8B077C-7ACE-4AC5-A942-B7D5A79198C5Q35434684-D22D2F19-BB9B-47BD-B37F-6644BDEFB867Q36002979-AE9DDCAC-7529-4109-BFCF-9E212CC0116DQ36080871-1F8C8463-6B2A-47A0-B4EB-A67C53764DE5Q36107581-D4E5A3BF-A0AC-4167-9F34-7F3B82EB5369Q36173462-829C23A2-2DCC-4B0E-83A3-1A5A8D06ABF5Q36283363-C7FCF842-A34D-4408-B4DC-8C1F6E2BA460Q36429587-628187BC-5A83-4F7A-8101-ADE2216C8521Q36686835-196E1231-DF4D-43C8-B1F9-04C935DFA4BFQ37175960-53E132DC-A397-4547-A419-B7AE836E3DC8Q37340390-97F6E685-A87A-4FC7-9F7B-5014A5E94461Q37481225-74322862-6459-431C-B2FF-D7AC86C7AAAAQ37513931-0E02FD31-963E-48B6-BF84-10FDC068E6DCQ38060714-07A7752A-7B8B-44D7-ABF8-EBC6D43C9755Q38099268-34063AF4-C4BC-41C4-AB06-E6D6FD6AF44BQ38166586-57E9BE96-423D-44CA-8110-BFE3E860BF91Q38294269-7BE87FB1-E52C-49EF-9076-EDF03E5C8A22Q38675999-E2B43F9C-37C1-4C06-905B-8A6CE4ECBDC7Q38694016-037BD000-E2CC-4D37-9A1D-3ADDC17F3C15Q40048508-53A70DF0-BA0E-4EE2-9160-B74D6C7AD617Q41463125-1CF099C6-E6D2-407C-A3D0-45340F2763BAQ41859957-2A4B8CF1-9D7C-491B-B97B-8EB7F6F62D5FQ41860885-7FEB5A9C-0240-4FB0-8938-6CF121208482Q42075975-381C68E5-2A40-4D1E-9B37-682295203DB2Q42267666-34D13EF0-8967-4E94-8562-30187126C2D4Q43053966-1B90CD8E-A87B-4E0E-8F68-C2E677F61E64
P2860
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@en
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@nl
type
label
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@en
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@nl
prefLabel
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@en
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@nl
P2093
P1476
Met proto-oncogene and insulin ...... ancreatic endocrine neoplasms.
@en
P2093
Anirban Maitra
Ayman Rahman
Charles J Yeo
Donna E Hansel
Karin Berg
Michael House
Raheela Ashfaq
P304
P356
10.1158/1078-0432.CCR-04-0285
P407
P433
P577
2004-09-01T00:00:00Z